Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Standard BioToolsSTU:FLB -6.29%39 OCF Yield % is -27.18 as of Jul. 14, 2026. GuruFocus rates STU:FLB with a GF Score™ of 39/100 and a GF Value™ of €0.46 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 852 Medical Devices & Instruments companies, Standard BioTools ranks worse than 87.79% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Standard BioTools's OCF Yield % or its related term are showing as below:
STU:FLB'
s OCF Yield % Range Over the Past 10 Years
Min: -94.99 Med: -17.04 Max: -2.77
Current: -27.18
During the past 13 years, the highest OCF Yield % of Standard BioTools was -2.77%. The lowest was -94.99%. And the median was -17.04%.
STU:FLB's OCF Yield % is ranked worse than 87.79% of 852
companies
in the Medical Devices & Instruments industry
Industry Median: 1.715
vs STU:FLB: -27.18
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Standard BioTools OCF Yield % Related Terms
Standard BioTools OCF Yield % Historical Data
* Premium members only.
The historical data trend for Standard BioTools's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:FLB vs SENS, TMCI, SGHT: OCF Yield % Comparison
For the Medical Devices subindustry, Standard BioTools's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Standard BioTools OCF Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Standard BioTools's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Standard BioTools's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Standard BioTools (STU:FLB) has a OCF Yield % of -27.18 as of Jul. 14, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Standard BioTools and its competitors. According to the industry distribution chart, Standard BioTools ranks #748 out of 852 companies in the Medical Devices & Instruments industry, placing it in the top 87.8%.
Is Standard BioTools' OCF Yield % too high?
Standard BioTools' current OCF Yield % is -27.18. Based on the distribution chart, Standard BioTools ranks #748 out of 852 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Standard BioTools has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Standard BioTools' OCF Yield % compare to SENS and TMCI?
According to the Medical Devices & Instruments industry distribution chart, Standard BioTools ranks #748 out of 852 companies for OCF Yield %. This places Standard BioTools in the lower half of its industry. The industry median OCF Yield % is 1.72. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Medical Devices & Instruments company?
The median OCF Yield % among Medical Devices & Instruments companies is 1.72, based on 852 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Standard BioTools and its competitors. For the Medical Devices & Instruments industry, the median OCF Yield % is 1.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Standard BioTools's current OCF Yield % is -27.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Standard BioTools stock overvalued right now?
Based on GuruFocus' analysis, Standard BioTools (STU:FLB) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.46, compared to a current price of €0.75 — trading 62% above its estimated fair value. The current OCF Yield % is -27.18. Standard BioTools' overall GF Score™ is 39/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Standard BioTools (STU:FLB), the current OCF Yield % is -27.18 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Standard BioTools (STU:FLB) Overvalued in 2026?
Based on GuruFocus' analysis, Standard BioTools stock appears to be overvalued.
The current stock price of €0.75 is trading 62% above its estimated GF Value™ of €0.46.
GuruFocus considers Standard BioTools to be Significantly Overvalued.
Key valuation signals for STU:FLB:
OCF Yield %: -27.18
GF Value™: €0.46 vs. price of €0.75 (62% above fair value)
No single metric tells the full story. See the STU:FLB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.
39GF Score
Get the complete analysis for STU:FLB
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:FLB has been successfully added to your 
